Macrophage activation syndrome

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Retrieved on: 
Wednesday, February 15, 2023

Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.” The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra™ for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources.

Key Points: 
  • Nes-Ziona, Israel, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 284985, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.” The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra™ for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources.
  • CAR T-cells are T-cells that have been genetically modified to include a receptor that allows them to specifically target and destroy cancer cells.
  • While certain CAR T-cell treatments were recently approved by the FDA in several cancer indications, such treatments have been associated in many patients with a side effect named cytokine release syndrome, which describes a collection of potentially severe or life-threatening symptoms that stem from over-activation of immune pathways.
  • Preclinical data indicate that Allocetra™ has the potential to prevent or ameliorate cytokine release syndrome associated with CAR T-cell therapies.

Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives

Retrieved on: 
Monday, December 6, 2021

The preclinical data indicates that the CCCMs may be effective anti-inflammatory therapies for CRS and other conditions such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS)-- all leading causes of death in COVID-19 patients.

Key Points: 
  • With reports of the arrival of the Omicron variant of the coronavirus in multiple countries, the Gb Sciences team plans to move quickly through the development stages for this novel CRS therapy.
  • "COVID variants are not going away anytime soon, and they will continue to cause health complications, particularly in unvaccinated individuals and older populations," said Dr. Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.
  • Gb Sciences' novel drug discovery platform has yielded three issued U.S. patents, as well as 8 U.S. and 39 international pending patent applications.
  • GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations.

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

Retrieved on: 
Tuesday, September 14, 2021

Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August18, 2021.

Key Points: 
  • Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August18, 2021.
  • Gb Sciences' proof-of-concept study was performed at Michigan State University using a state-of-the-science human immune model.
  • "Gb Sciences' novel cannabinoid-containing mixtures showed potential for immunomodulation of pro-inflammatory processes in our human immune cell model," said Dr. Kaminski.
  • In addition to Parkinson's disease, Gb Sciences is developing therapeutics forCOVID-related cytokine release syndrome (CRS), chronic pain, Mast Cell Activation Syndrome (MCAS), and heart failure.

Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit

Retrieved on: 
Tuesday, August 31, 2021

Patients were heavily pre-treated, having received an average of six prior lines of therapy with a median time since diagnosis of 6.4 years.

Key Points: 
  • Patients were heavily pre-treated, having received an average of six prior lines of therapy with a median time since diagnosis of 6.4 years.
  • "This is the first time that I have seen such impressive responses with an immunotherapy product.
  • The Phase 1 trial is an open label, multi-center, 3+3 dose-escalating study designed to assess the safety of P-PSMA-101 in up to 40 adult subjects with mCRPC.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.